Conjugated linoleic acid in treatment and prophylaxis of diabetes
AssigneeNatural Corporation
InventorsJan Remmereit, Jan Wadstein, Jo Klaveness
Life of this patent
Estimating the term…
Abstract
This invention provides method of treatment and prophylaxis of both insulin (Type I) and non-insulin dependent (type II) diabetes mellitus, by administration of conjugated linoleic acid (CLA) in the form of pure isomers, selected isomer mixtures or non-selected isomer mixtures. The conjugated linoleic acids may be administered alone, or in combination with other diabetes therapeutic regimes.
Claims46
A method of treating symptoms of diabetes in a human comprising:
- a) providing
- i) a therapeutically effective amount of conjugated linoleic acid;
- and
- ii) a human patient suffering from diabetes;
- and
- b) administering said therapeutically effective amount of conjugated linoleic acid to said human diabetic patient under conditions such that said symptoms of diabetes are treated.
A method of treating diabetes comprising:
- a) providing
- i) a therapeutically effective amount of conjugated linoleic acid;
- and
- ii) a human patient suffering from diabetes;
- and
- b) administering said therapeutically effective amount of conjugated linoleic acid to said human diabetic patient, wherein the percentage of glycosylated hemoglobin in the blood of said human patients is reduced, and wherein said therapeutically effective amount of conjugated linoleic acid comprises a daily dosage of about 0.05 to 40 grams.
A method of treatment, comprising:
- a) providing:
- i) a human patient at risk for diabetes, and
- ii) a therapeutic composition comprising an effective amount of conjugated linoleic acid;
- and
- b) prophylactically administering said therapeutic composition to said human patient under conditions such that the risk of diabetes is reduced, wherein said effective amount of conjugated linoleic acid comprises a daily dosage of about 0.05 to 40 grams.
A method of reducing glycosylated hemoglobin in the blood of human diabetic patients comprising:
- a) providing
- i) an anti-hyperglycemia agent and a therapeutically effective amount of conjugated linoleic acid;
- and
- ii) a human patient suffering from diabetes;
- and
- b) co-administering said antihyperglycemia agent and said therapeutically effective amount of conjugated linoleic acid to said human diabetic patient under conditions such that the percentage of glycosylated hemoglobin in blood of said human patients is reduced, wherein said therapeutically effective amount of conjugated linoleic acid comprises a daily dosage of about 0.05 to 40 grams.
Dependencies are inferred from the claim text.